Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026

Same author

Building Public Health Leadership Capacity Through Community-Based Education: The Florida Health Policy Leadership Academy.

American journal of preventive medicine·2026

Same author

Poxvirus attack of antiviral defense pathways unleashes an effector-triggered NF-κB response.

Science (New York, N.Y.)·2026

Same author

Impact Of Housing Support Services For Medicaid Enrollees With Serious Mental Illness, Substance Use Disorder.

Health affairs (Project Hope)·2026

Same author

Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.

Scientific reports·2025

Same author

Exploring the association between supportive school policy and youth tobacco use.

Public health·2025

Search research articles

Related Experiment Video

Updated: May 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic virotherapy for hematological malignancies.

Swarna Bais¹, Eric Bartee, Masmudur M Rahman

¹Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, ARB R4-202, P.O. Box 100278, Gainesville, FL 32610-0278, USA.

Advances in Virology

|February 8, 2012

Summary

Oncolytic viruses offer a promising solution for purging cancer cells from patient stem cell transplants. These viruses selectively target malignant cells, preserving healthy stem cells and reducing transplant relapse risks.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Experiment Videos

Last Updated: May 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Area of Science:

Hematology
Oncology
Virology

Background:

Hematological malignancies like leukemia and multiple myeloma are challenging to treat.
Hematopoietic stem cell transplant (HCT) is a high-risk treatment option.
Autologous HCT faces relapse challenges due to residual cancer cells in grafts.

Purpose of the Study:

To explore oncolytic viruses as a method for ex vivo purging of autografts.
To evaluate the potential of specific oncolytic viruses in eliminating contaminating cancer cells.
To assess the safety and efficacy of oncolytic virus purging for HCT.

Main Methods:

Review of experimental progress with various oncolytic viruses (reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, vaccinia virus).
Assessment of viral specificity for malignant cells versus normal hematopoietic stem and progenitor cells.
Evaluation of requirements for clinical translation of oncolytic virus purging strategies.

Main Results:

Oncolytic viruses demonstrate potential for selective cancer cell targeting.
Traditional ex vivo purging methods often harm normal stem cells, leading to complications.
Oncolytic viruses offer a more specific and potentially less toxic purging approach.

Conclusions:

Oncolytic viruses represent an ideal candidate for ex vivo autograft purging.
Successful clinical translation requires further research into viral selection and application protocols.
Oncolytic virus therapy could significantly improve outcomes for patients undergoing autologous HCT.